The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2020

Filed:

Feb. 12, 2016
Applicant:

University of Massachusetts, Boston, MA (US);

Inventors:

Guangping Gao, Westborough, MA (US);

Phillip D. Zamore, Northborough, MA (US);

Dan Wang, Belchertown, MA (US);

Assignee:

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/22 (2006.01); A61K 48/00 (2006.01); C12N 15/90 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/11 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/22 (2013.01); A61K 48/005 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); A61K 38/00 (2013.01); C07K 2319/735 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14121 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14142 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The disclosure in some aspects relates to recombinant adeno-associated viruses having nuclease grafted to one or more capsid proteins. In some aspects, the disclosure relates to isolated AAV capsid proteins having terminally grafted nucleases and isolated nucleic acids encoding the same. Recent approaches to delivering nucleases to cells for gene editing have focused on delivering of expression vectors engineered to express the nucleases in target cells. However, these approaches have proved to be problematic in many instances due to genotoxicity resulting from to prolonged expression of gene editing system in vivo. To prevent such off-target genotoxicity due to prolonged presence of a gene editing system, several studies explored delivery of mRNA or protein instead of delivering the gene coding for the nucleases in cell culture.


Find Patent Forward Citations

Loading…